Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
The overall survival benefit with ribociclib increased over time.
Diagnosis & Disease Information
Durvalumab Plus Chemo Showed Continued Survival Benefit in Extensive-Stage SCLC
Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.
Adjuvant Pembrolizumab Prolongs Relapse-Free Survival in Stage II Melanoma
Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
Novel Antibody-Drug Conjugate May Improve PFS in Advanced Breast Cancer
SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive breast cancer.
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Enzalutamide Plus ADT Prolongs Survival in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Median OS was not reached for the T-VEC plus pembrolizumab arm and 49.2 months for the placebo plus pembrolizumab arm.
Trastuzumab Deruxtecan: A New Standard for Second-Line Therapy in HER2+ Metastatic Breast Cancer?
Trastuzumab deruxtecan significantly improved progression-free survival.
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
- Loading...
Loading...
Next post in ESMO 2021
Loading... 
Loading...